The Quality of Care and Economic Burden of COPD in the United States: Considerations for Managing Patients and Improving Outcomes

June 2022 Vol 15, No 2 - Clinical, Review Article
David L. Larsen, RN, MHA; Hitesh Gandhi, MBBS; Michael Pollack, MS; Norbert Feigler, MD; Sushma Patel, PharmD; Robert A. Wise, MD
Mr Larsen is Director, Quality Improvement, SelectHealth, Murray, UT; Dr Gandhi is Implementation Science Director, Mr Pollack is Director, US Payer Evidence, Respiratory and Immunology Franchise Lead, Dr Feigler is Senior Medical Director, Respiratory, and Dr Patel is National Clinical Account Director, AstraZeneca, Wilmington, DE; Dr Wise is Professor of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Download PDF
Abstract

BACKGROUND: The economic and societal burdens of chronic obstructive pulmonary disease (COPD) in the United States are substantial and increasing. COPD had projected US costs of $49 billion in 2020, and chronic lower respiratory diseases, including COPD, were the fourth leading cause of death in the United States in 2019. COPD-related hospitalizations for exacerbations are the greatest driver of costs; however, numerous factors shape the current landscape of COPD, and thus multiple opportunities to improve quality of care for patients are being explored.

OBJECTIVES: To describe the existing burden, unmet needs, and related economics of COPD in relation to quality of care and to discuss approaches to reduce the cost of managing COPD, including advancements in maintenance therapy.

DISCUSSION: Comorbidities are associated with increased hospitalizations and costs, worse outcomes, and reduced quality of life in patients with COPD. The severity of COPD and the rate of exacerbations are important drivers of medical costs, which highlights the importance of early diagnosis, early recognition of exacerbations, and timely initiation of therapy. The reduction of COPD hospital readmissions is of critical importance to reduce costs, per the recommendations of organizations such as the Centers for Medicare & Medicaid Services. Performance measures offered by the Healthcare Effectiveness Data and Information Set are a helpful tool; however, objective data evaluating how improving the quality of COPD care translates to reduced costs to the healthcare system are lacking.

CONCLUSION: A comprehensive strategy to reduce COPD mortality and clinical burden will require a multifaceted approach. Key methods include improved patient access to care; early intervention with appropriate, effective treatment, such as single-inhaler triple therapies; proactive adherence monitoring; early recognition of worsening COPD and modification of treatment; disease management strategies, including smoking cessation and pulmonary rehabilitation; and evidence-based metrics to evaluate hospital readmission programs.

Key Words: access to care, adherence, chronic obstructive pulmonary disease, COPD, cost-effectiveness, economic burden, exacerbations, GOLD report, hospital readmissions, multiple-inhaler triple therapy, single-inhaler triple therapy

Am Health Drug Benefits.
2022;15(2):57-64

Manuscript received August 17, 2021
Accepted in final form February 10, 2022

Disclosures are at end of text

Chronic obstructive pulmonary disease (COPD) is a preventable, treatable illness characterized by airflow limitation and persistent respiratory manifestations, including shortness of breath, chronic cough, and excess sputum production. Chronic lower respiratory diseases were the fourth leading cause of death in the United States in 2019.1 COPD is underdiagnosed by primary care physicians because of inconsistent patient reporting of symptoms, time constraints for management of multiple comorbidities, lack of access to spirometry, unfamiliarity with the most recent Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, and unfamiliarity with spirometry interpretation.2

Among chronic conditions, COPD is one of the most costly, estimated to total $49 billion in 2020.2,3 COPD-related medical costs increase with increasing disease severity; those with very severe COPD incurred nearly 3 times the annual costs of those with mild COPD ($18,070 vs $5945, respectively).4

Patients with COPD have substantial comorbid disease burden, including cardiovascular diseases, metabolic disorders, osteoporosis, skeletal muscle dysfunction, anxiety/depression, and gastrointestinal diseases,5 and this burden is associated with greater healthcare resource use,6 complexity of management, and costs of care (Figure 1).7 Thus, COPD should be a high-priority disease for US providers and payers to manage appropriately, especially in the context of COVID-19, for which COPD is a risk factor for severity and mortality.8,9

Figure 1

Patients with COPD who become infected with COVID-19 are at higher risk for severe illness and mortality; therefore, vaccination against COVID-19 is recommended.10,11 Considerations for device and medication selection for patients in the context of COVID-19, including strategies for at-home administration of aerosolized medications for patients with COPD, have been discussed elsewhere.12 A substantial reduction in COPD hospitalizations during the COVID-19 pandemic has been noted13 and has been attributed to the widespread use of masks and social distancing, which resulted in reductions in viral respiratory illness.

The objectives of this review are to describe the existing burden, unmet needs, and related economics of COPD in relation to quality of care and to discuss quality-of-care metrics and maintenance medications that could reduce the cost of managing COPD, including advancements in single-inhaler triple therapy.

Impact of Exacerbations

A COPD exacerbation is an acute worsening of respiratory symptoms that results in additional therapy; exacerbations are graded as mild, moderate, or severe based on the intensity of resources needed to treat the event.14 Exacerbations negatively affect patients and payers in terms of disease morbidity/mortality and healthcare costs, respectively. The ECLIPSE study found that a strong predictor of future exacerbations was a previous exacerbation.15

A subsequent US administrative claims database study found that patients with severe COPD had nearly twice the rate of exacerbations per 100 person-years versus patients with mild COPD.4 Patients with less severe COPD still experience exacerbations15,16; therefore, efforts toward exacerbation prevention should be considered across the spectrum of disease severity.

Links between exacerbation history and future risks may be explained in part by the long-term sequelae of exacerbations. Moderate and severe COPD exacerbations can accelerate loss of lung function most potently in patients with mild to moderate disease (GOLD grade 1 or 2) again emphasizing the importance of earlier identification and intervention for future exacerbation prevention.17 Even among those with less severe COPD, significant reductions in lung function were observed with severe (hospitalized) exacerbations.17

Exacerbation incidence is associated with increased risk for morbidity and mortality. In a large database study, patients who had ≥1 severe exacerbations at baseline had an increased risk for death (hazard ratio, 1.79; 95% confidence interval, 1.65-1.94) compared with those without exacerbations.18 A large multicenter study has shown that patients who experience COPD exacerbations had a nearly 4-fold increased risk for cardiovascular events within 30 days after a hospitalized exacerbation, with increased risk extending up to 1 year after an event.19

After a moderate COPD exacerbation, patients have double the risk for myocardial infarction within 5 days of the event compared with those with stable disease, whereas the risk for stroke was significantly increased during days 1 to 49 following exacerbation.20 Recognizing exacerbations and their relationship with other costly comorbidities and subsequently adjusting therapy accordingly may help prevent future events, thereby reducing overall burden.

Hospitalization and Readmission Rates

Although the length of hospitalization among patients with COPD has decreased in recent years, the number of admissions remains unchanged, highlighting the continued burden of severe exacerbations for these patients.21

The 30-day hospital readmission rate for COPD was 19.2%; rates for frequent hospitalizations for COPD (≥2 events) and for patients with ≥4 comorbidities were 35.3% and 24.5%, respectively.22 Among patients with COPD and ≥2 severe exacerbations within the past year, COPD-related 30-day readmissions are most frequent for those with Medicare fee-for-service compared with patients with a commercial payer, managed Medicaid, or Medicare Advantage (Figure 2).23

Figure 2

This disparity suggests room for improvement in readmissions in Medicare fee-for-service, especially compared with Medicare Advantage, perhaps due to more focused COPD management in Medicare Advantage. Data suggest that, along with previous COPD hospitalization, age, comorbid anxiety, depression, asthma, diabetes, dyspnea, hypoxia, ischemic heart disease, and pneumonia are predictors for COPD-related readmissions.24

Given that patients with COPD can experience significant rates of hospitalization and readmission, it is important to note that COPD is considered an ambulatory care–sensitive condition, as are many of its comorbid conditions. The ambulatory care–sensitive condition designation means that severe exacerbations can be reduced with better primary care management, focus on prevention, and adherence to maintenance therapy, thus avoiding inpatient- and emergency department–related costs.25,26 Appropriate access to and coordination with pulmonary care specialists is also a significant factor in reducing hospitalization for COPD.27

Management of COPD from a Quality Measures Perspective

Due to the frailty of patients with COPD and the complexity of the condition, it is important that patients receive comprehensive high-quality care to relieve symptoms and to prevent future exacerbations and hospitalizations. Ultimately, this should reduce the overall burden and associated healthcare costs of COPD.

Several of the most widely used performance measures in the Healthcare Effectiveness Data and Information Set (HEDIS) are COPD-related, such as use of spirometry testing, yet data seem to indicate that minimal gains have been achieved with quality-of-care initiatives and that noticeable gaps remain.28 For example, despite the use of the HEDIS measure Hospitalization for Potentially Preventable Complications for Ambulatory Care Sensitive Conditions, COPD-related hospitalizations and readmissions remain high.29

Although several current quality measures focus on spirometry, these measures may fall short in truly supporting quality of care,28 perhaps due to structural barriers found in many local healthcare systems and primary care practices. For instance, spirometry may not be available to all patients and may not be practical to administer in a primary or specialty care setting.

In addition, the Pharmacotherapy Management of COPD Exacerbation measure does not take into consideration the evaluation of long-acting maintenance therapy after an exacerbation30; instead it is focused on short-term use of bronchodilators and systemic corticosteroids. Finally, although general measures of all-cause readmissions and follow-up after emergency department visits seek to improve care coordination, communications challenges persist, as the initiatives may not be specific enough to address the unique needs of patients with COPD, who may need specialist referrals or further treatment evaluation.31

The Centers for Medicare & Medicaid Services (CMS), a major payer of COPD-related care in the United States, levies financial penalties against hospitals with excess 30-day, all-cause readmissions after a hospitalization through their Hospital Readmissions Reduction Program (HRRP).32

CMS data show substantial differences in COPD 30-day readmission rates among hospitals (median, 19.7%; range, 16.2%-26.8%)33 and COPD-related costs by state, indicating significant regional variation.34 A recent study found that in Medicare’s HRRP hospitals, the excess readmissions ratio for COPD decreased by 3.8% from 2016 to 2019 compared with an increase of 3.7% in non-HRRP hospitals.35 It is worrisome, however, that the reduction in readmissions was associated with an increase in mortality, which highlights the continued complexity and need to further understand COPD patient care.36,37

Although the prevalence of COPD is highest among the Medicare-aged population (≥65 years),36 the Medicare Stars ratings related to managing chronic (long-term) conditions for Medicare Part C plans make no specific mention of COPD.38 A component of the Medicare Stars measurements for Part D plans includes a comprehensive medication review for patients with COPD within 30 days post discharge; furthermore, CMS mandates that health plans administer pharmacologic management programs at no cost to qualified members.39

In addition to focusing on readmissions, the American Thoracic Society has recommended that programs address quality of care using other patient-centered metrics, such as mortality, patient satisfaction, adherence, self-efficacy, symptoms, and exercise tolerance to evaluate programs aimed to reduce readmissions and improve COPD care.40 In light of these current measures and apparent gaps, quality measures should advance beyond current measures to include the following: improved coordination at the time of diagnosis, care transitions, and clinical deterioration; improved patient identification and prompt access to outpatient healthcare; proper disease management, including high-quality outpatient care; attempts to improve maintenance medication adherence29; and recognition of high-risk factors associated with hospital readmissions.22

Specific interventions recommended as best practices by the American Thoracic Society that could be integrated into new quality measures include smoking cessation, inhaler device use instruction, follow-up care with a multidisciplinary team, and referrals to pulmonary rehabilitation.40 Implementation of integrated care for patients with COPD has demonstrated cost-savings driven by reduced hospitalizations.41

A Proactive Approach to COPD Management
Importance of Appropriate and Effective Therapy

Although maintenance pharmacotherapy for COPD has not been proved to modify long-term lung function decline, appropriate treatment can reduce symptoms and the frequency and severity of exacerbations, improving exercise tolerance and health status for patients.14 The classifications of medications used to treat COPD according to GOLD guidelines include short- and long-acting bronchodilators (β2-agonists and antimuscarinic drugs prescribed individually or in combination), inhaled corticosteroids (ICS), methylxanthines, phosphodiesterase-4 inhibitors, mucolytic agents, and chronic macrolide therapy.14

Severity of symptoms, airflow limitation, severity of exacerbations, and availability and cost of medication should be taken into consideration when prescribing initial maintenance therapy, which should achieve a favorable clinical response balanced against side effects.14 The value of prompt initiation of maintenance therapy after a COPD-related hospitalization has been demonstrated through reduced COPD-related costs and risk for future exacerbations.42

Equally important is the continual assessment of the effectiveness of treatment; GOLD guidelines provide recommendations for therapy escalation/de-escalation based on the persistence of exacerbations and other symptoms derived from evidence from randomized controlled trials and clinical experience.14

A recent study found that 49.2% of patients across payers did not fill any maintenance therapy over 12 months after initial diagnosis of COPD, demonstrating an apparent lack of treatment initiation and the loss of substantial opportunities for earlier intervention and improved patient outcomes.43

The current approach of accelerating treatment in response to treatment failure leaves patients susceptible to recurrent exacerbations, which are associated with worsening of symptoms and lung function decline.44 Furthermore, given that nearly half of exacerbation events may go unreported and thus untreated,45 this approach may come too late for many patients. Instead, providers should ensure that patients are receiving the appropriate maintenance therapy with superior efficacy in reducing the rate of exacerbations.

Adherence to maintenance therapy is critical to manage symptoms but more importantly to decrease future exacerbation risk, as nonadherence is associated with higher exacerbation rates and therefore increased healthcare costs. Individualizing inhalation devices according to patient preference, including inhaler training; broadening access to various therapies; and simplifying treatment regimens could potentially improve adherence and outcomes.14,46,47

The GOLD report emphasizes the importance of training in inhaler technique, citing the relationship between poor inhaler technique and symptom control.14 Thus, proper device selection and training are important for optimal COPD care.47 Although GOLD recommendations do not explicitly mention assessing a patient’s underlying socioeconomic status when evaluating treatment options, it is likely that these factors should be considered in daily practice to ensure patient access and understanding of treatment options.

Pharmacologic Therapy Considerations

The most recent addition to the available classes of pharmacologic therapy for COPD is single-inhaler triple therapy, consisting of combinations of ICS and bronchodilators. The GOLD report recommends single-inhaler triple therapy for patients with a history of frequent and/or severe exacerbations currently receiving separate triple therapy, dual ICS/long-acting β2-agonist (LABA), or single or dual long-acting bronchodilators, based on the results of several pivotal clinical trials within this population.14

As with maintenance therapy in general, prompt initiation of triple therapy after a COPD-related hospitalization or emergency department visit may reduce future costs and subsequent exacerbations.48,49 Single-inhaler triple therapy has not been studied in patients naïve to pharmacologic treatment and therefore may not be appropriate as initial maintenance therapy for every patient with COPD. Nonetheless, real-world evidence within and outside of the United States indicates that 20.4% of patients naïve to maintenance therapy were deemed to have disease severe enough to warrant initiation of triple therapy.50

The single-inhaler triple therapies currently available in the United States include an ICS plus a long-acting muscarinic antagonist (LAMA) and a LABA in 1 inhaler device. The first single-inhaler triple therapy study was the IMPACT trial, which assessed fixed-dose ICS/LAMA/LABA triple therapy (fluticasone furoate/umeclidinium/vilanterol) compared with ICS/LABA and LAMA/LABA in 10,355 patients with symptomatic, moderate to severe COPD and ≥1 exacerbation in the year before the trial, over a 52-week period. Single-inhaler triple therapy significantly reduced the rate of moderate or severe COPD exacerbations compared with ICS/LABA and LAMA/LABA.51

The most recent large single-inhaler triple-therapy trial (ETHOS) assessed budesonide/glycopyrrolate/formoterol fumarate (BGF) inhaler versus ICS/LABA and LAMA/LABA in 8588 symptomatic patients with moderate to severe COPD (including forced expiratory volume in 1 second from 25% to 65% and ≥1 moderate or severe exacerbations in the previous year) over 52 weeks; all interventions were administered via metered-dose inhalers. The 320/18/9.6-µg BGF (BGF 320) and the 160/18/19.6-µg BGF (BGF 160) groups demonstrated significantly lower annual rates of moderate or severe exacerbations compared with patients receiving LAMA/LABA and ICS/LABA.52

The KRONOS study compared BGF 320 with LAMA/LABA, ICS/LABA, and an open-label ICS/LABA dry-powder inhaler in 1902 patients with moderate to severe COPD over 24 weeks.53 Unlike the other triple-therapy studies, 74% of the patients in KRONOS had no exacerbations in the previous year. BGF 320 significantly improved lung function versus ICS/LABA at 24 weeks, with a numerical difference versus LAMA/LABA. As a secondary end point, BGF 320 reduced moderate or severe exacerbations by 20% versus the LAMA/LABA comparator.53

All-cause mortality was assessed in 2 trials, as a predefined secondary end point in ETHOS and an end point in IMPACT.54,55 In the final data set from ETHOS, all-cause mortality over 52 weeks, on and off treatment, was significantly reduced by 49% for BGF 320 versus LAMA/LABA. A 28% reduction was observed versus ICS/LABA.54 In IMPACT, all-cause mortality was reduced by 28% compared with LAMA/LABA and by 11% versus ICS/LABA for on- and off-treatment deaths.51,55 The recent GOLD guidelines have acknowledged that the results emerging from these large trials suggest a beneficial trend of single-inhaler triple therapy versus fixed-dose LABA/LAMA to reduce mortality risk, although additional evidence may help determine whether survival benefits are greater within specific patient subgroups.14

In addition to preventing exacerbations and reducing mortality, single-inhaler triple therapy has the potential benefit of improving patient adherence by simplifying treatment,56 provided that single-inhaler triple therapy has equivalent or superior efficacy to multiple-inhaler triple therapies. In a recent study, Ferguson and colleagues conducted identical phase 4 trials comparing the efficacy and safety of 2 ICS/LAMA/LABA combination therapies: a single-inhaler triple therapy (fluticasone furoate, umeclidinium, and vilanterol) and a multiple-inhaler triple therapy (budesonide, formoterol fumarate, and tiotropium) in patients with symptomatic COPD.57 The single-inhaler triple therapy was noninferior to multiple-inhaler triple therapy, demonstrating similar improvements in lung function and health status, although the study’s 12-week duration precluded assessment of exacerbation frequency.57 A meta-analysis of studies comparing single-inhaler triple therapy and multiple-inhaler triple therapy found no difference in risk of moderate or severe exacerbations.58 These results support single-inhaler triple therapy as a viable option to simplify treatment for patients receiving multiple-inhaler triple therapy.

Other Considerations in Managing COPD

Respiratory infections are the leading cause of COPD exacerbations; GOLD and various guidelines indicate that rates of acute exacerbations are lower among those who have received influenza and pneumococcal vaccines.59,60 Lifestyle interventions can also lessen COPD burden: smoking cessation slows lung function decline and reduces hospitalization and mortality.61

Pulmonary rehabilitation as part of integrated patient management can improve symptoms, health-related quality of life, and physical and social participation in daily activities; it also reduces readmission rates, emergency department visits, and medical costs,14,47,62 and may reduce mortality after COPD hospitalization.63

Although pulmonary rehabilitation and triple therapies have clear benefits, the lack of care coordination throughout the health system suggests that appropriate discharge protocols or transitions of care programs from the inpatient to outpatient settings after a severe exacerbation are needed to ensure appropriate consideration of these treatment options.64 Discontinuation of maintenance therapy is known to increase risk of exacerbations65; the transition of care between the hospital and outpatient setting requires further focus to ensure discontinuation does not occur.

Finally, holistic strategies including improved surveillance, education of healthcare providers and the public about COPD, improved access to cost-effective and affordable healthcare, emphasis on smoking cessation, and minimizing environmental and occupational exposures could help alleviate the burden of COPD in people of lower socioeconomic status.66 Opportunities exist to improve quality of care for patients while reducing the economic burden for payers.67,68

Conclusions

Individual and societal burdens of COPD are high. Multiple strategies exist to reduce exacerbation and hospitalization rates, including ensuring high-quality outpatient care, implementing transitions of care, improving physician awareness of current treatment guidelines, and increasing patient adherence to medications and disease management strategies. Earlier diagnosis and more proactive treatment with appropriate maintenance therapies that account for patients’ comorbidities are critical for improving patient health-related quality of life and reducing costs, exacerbations, and mortality.

Practitioners should consider the most recent scientific data and pharmacotherapy available, including single-inhaler triple therapies that show better reductions of exacerbations and improvements in all-cause mortality compared with monotherapy or dual therapy in patients with frequent exacerbations. Although HEDIS and CMS activities provide valuable strategies to the payer and encourage the reduction of readmissions, there is still a relative lack of quality measures designed specifically to improve quality of care for patients with COPD. Additional opportunities to develop quality measures targeting care coordination and treatment escalation should include lessons from other disease states to ensure that quality care is being delivered in a proactive and appropriate manner. Overall, better coordination between primary, specialty, and inpatient care teams, and the optimization of pharmacologic management can improve quality of life for patients and reduce the substantial emergency department and hospitalization costs associated with COPD.

Acknowledgments
Medical writing support was provided by Analise Berkelbach, PhD, of MedErgy/Cello Health Communications.

Funding Source
The funding for this article was provided by AstraZeneca, including the funding for the medical writing support, in accordance with Good Publication Practice (GPP3) guidelines. The decision to submit the manuscript for publication was made by the authors.

Author Disclosure Statement
Dr Gandhi, Mr Pollack, Dr Feigler, and Dr Patel are employees and shareholders of AstraZeneca. Dr Wise has received compensations from AstraZeneca, Boehringer Ingelheim, Chiesi, ContraFect, Novartis, Roche-Genentech, GlaxoSmithKline, Merck, Verona, Mylan/Theravance, AbbVie, Chimerx, Kiniksa, Bristol Myers Squibb, Galderma, Kamada, Pulmonx, Kinevant, PureTech, and Arrowhead. Mr Larsen has no conflicts of interest to report.

References

  1. Kochanek KD, Xu J, Arias E. Mortality in the United States, 2019. National Center for Health Statistics Data Brief, No 395. Hyattsville, MD: National Center for Health Statistics; December 2020. www.cdc.gov/nchs/data/databriefs/db395-H.pdf. Accessed December 15, 2021.
  2. Criner RN, Han MK. COPD care in the 21st century: a public health priority. Respir Care. 2018;63:591-600.
  3. Priest JL, Cantrell CR, Fincham J, et al. Quality of care associated with common chronic diseases in a 9-state Medicaid population utilizing claims data: an evaluation of medication and health care use and costs. Popul Health Manag. 2011;14:43-54.
  4. Wallace AE, Kaila S, Bayer V, et al. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J Manag Care Spec Pharm. 2019;25:205-217.
  5. Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: impact, measurement and mechanisms. Respirology. 2015;20(8):1160-1171.
  6. Powell D, Pollack M, Moretz C, et al. Assessment of healthcare resource use by comorbidity burden among COPD patients diagnosed across multiple payer settings. J Manag Care Spec Pharm. 2020;26(10-a suppl):S58.
  7. Xi A, Make B, Moretz C, et al. Evaluating total all-cause and COPD-related costs by comorbidity burden in patients with Medicare fee-for-service. J Manag Care Spec Pharm. 2020;26(10-a suppl):S58-S59.
  8. Ge E, Li Y, Wu S, et al. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: a population-based cohort study. PLoS One. 2021;16:e0258154.
  9. Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020;15:e0233147.
  10. Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed April 19, 2021.
  11. Meza D, Khuder B, Bailey JI, et al. Mortality from COVID-19 in patients with COPD: a US study in the N3C data enclave. Int J Chron Obstruct Pulmon Dis. 2021;16:2323-2326.
  12. Ari A, Blain K, Soubra S, Hanania NA. Treating COPD patients with inhaled medications in the era of COVID-19 and beyond: options and rationales for patients at home. Int J Chron Obstruct Pulmon Dis. 2021;16:2687-2695.
  13. Chan KPF, Ma TF, Kwok WC, et al. Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic. Respir Med. 2020;171:106085.
  14. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2022 Report. 2021. https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed December 15, 2021.
  15. Hurst JR, Vestbo J, Anzueto A, et al; for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128-1138.
  16. 16. Dreyfus J, Moretz C, Kumar S, et al. Does baseline exacerbation history in COPD predict future exacerbation frequency? Real world insights from multiple US insurers. Am J Respir Crit Care Med. 2021;203:A2297.
  17. Dransfield MT, Kunisaki KM, Strand MJ, et al; for the COPD Gene investigators. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:324-330.
  18. Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice–based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198:464-471.
  19. Kunisaki KM, Dransfield MT, Anderson JA, et al; for the SUMMIT investigators. Exacerbations of chronic obstructive pulmonary disease and cardiac events: a post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198:51-57.
  20. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137:1091-1097.
  21. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235-245.
  22. Goto T, Faridi MK, Gibo K, et al. Trends in 30-day readmission rates after COPD hospitalization, 2006-2012. Respir Med. 2017;130:92-97.
  23. Dreyfus J, Moretz C, Make B, et al. Descriptive real-world payer comparisons of exacerbation frequency and healthcare resource utilization after COPD diagnosis. Chest. 2020;158(4 suppl):1685A-1686A.
  24. Roberts MH, Clerisme-Beaty E, Kozma CM, et al. A retrospective analysis to identify predictors of COPD-related rehospitalization. BMC Pulm Med. 2016;16:68.
  25. Purdy S, Griffin T, Salisbury C, Sharp D. Ambulatory care sensitive conditions: terminology and disease coding need to be more specific to aid policy makers and clinicians. Public Health. 2009;123:169-173. Erratum in: Public Health. 2010;124:720.
  26. Galarraga JE, Mutter R, Pines JM. Costs associated with ambulatory care sensitive conditions across hospital-based settings. Acad Emerg Med. 2015;22(2):172-181.
  27. Kim M, Ren J, Tillis W, et al. Explaining the link between access-to-care factors and health care resource utilization among individuals with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:357-367.
  28. National Committee for Quality Assurance. Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR). www.ncqa.org/hedis/measures/use-of-spirometry-testing-in-the-assessment-and-diagnosis-of-copd/. Accessed May 8, 2020.
  29. Centers for Medicare & Medicaid Services. ACO #9—Prevention quality indicator (PQI): ambulatory care sensitive conditions: admissions for chronic obstructive pulmonary disease (COPD) or asthma in older adults. 2016. www.cms.gov/medicare/medicare-fee-for-service-payment/sharedsavingsprogram/downloads/measure-aco-9-asthma.pdf. Accessed May 8, 2020.
  30. National Committee for Quality Assurance. Pharmacotherapy Management of COPD Exacerbation (PCE). www.ncqa.org/hedis/measures/pharmacotherapy-management-of-copd-exacerbation/. Accessed May 8, 2020.
  31. National Committee for Quality Assurance. Follow-Up After Emergency Department Visit for People with High-Risk Multiple Chronic Conditions (FMC). www.ncqa.org/hedis/measures/follow-up-after-emergency-department-visit-for-people-with-high-risk-multiple-chronic-conditions/. Accessed March 17, 2020.
  32. Centers for Medicare & Medicaid Services. Hospital Readmissions Reduction Program (HRRP). www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program. Accessed May 8, 2020.
  33. Centers for Medicare & Medicaid Services; Yale New Haven Health Services Corporation-Center for Outcomes Research and Evaluation. Variation in 30-day readmission rates across hospitals following hospitalizations for acute myocardial infarction, chronic obstructive pulmonary disease, heart failure, pneumonia, and acute ischemic stroke. September 2017. www.cmshospitalchartbook.com/sites/default/files/Distributions_CS%20RSRR.pdf. Accessed December 15, 2021.
  34. Sullivan J, Pravosud V, Mannino DM, et al. National and state estimates of COPD morbidity and mortality–United States, 2014-2015. Chronic Obstr Pulm Dis. 2018;5:324-333.
  35. Hoffman GJ, Yakusheva O. Association between financial incentives in Medicare’s Hospital Readmissions Reduction Program and hospital readmission performance. JAMA Netw Open. 2020;3:e202044.
  36. Puebla Neira DA, Hsu ES, Kuo YF, et al. Readmissions reduction program: mortality and readmissions for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203:437-446.
  37. Wheaton AG, Liu Y, Croft JB, et al. Chronic obstructive pulmonary disease and smoking status—United States, 2017. MMWR Morb Mortal Wkly Rep. 2019;68:533-538.
  38. Centers for Medicare & Medicaid Services. Medicare 2020 Part C & D Star Ratings technical notes. Updated October 1, 2019. www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/Downloads/Star-Ratings-Technical-Notes-Oct-10-2019.pdf. Accessed December 15, 2021.
  39. Centers for Medicare & Medicaid Services. Medication therapy management. www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/MTM. Accessed November 13, 2020.
  40. Press VG, Au DH, Bourbeau J, et al; for the American Thoracic Society Behavioral Science and Health Services Research, Clinical Problems, and Nursing Assemblies. Reducing chronic obstructive pulmonary disease hospital readmissions: an official American Thoracic Society Workshop Report. Ann Am Thorac Soc. 2019;16:161-170.
  41. Trout D, Bhansali AH, Riley DD, et al. A quality improvement initiative for COPD patients: a cost analysis. PLoS One. 2020;15:e0235040. Erratum in: PLoS One. 2021;16:e0249844.
  42. Coutinho AD, Lokhandwala T, Boggs RL, et al. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population. Int J Chron Obstruct Pulmon Dis. 2016;11:1223-1231.
  43. Moretz C, Make B, Parente A, et al. Real-world evidence of initial medication fills after chronic obstructive pulmonary disease (COPD) diagnosis: a multiple-payer analysis. Poster presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition; December 6-10, 2020.
  44. Watz H, Tetzlaff K, Magnussen H, et al. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respir Res. 2018;19:251.
  45. Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXAcerbations of Chronic Pulmonary Disease Tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11:316-325.
  46. Braido F, Lavorini F, Blasi F, et al. Switching treatments in COPD: implications for costs and treatment adherence. Int J Chron Obstruct Pulmon Dis. 2015;10:2601-2608.
  47. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2021 Report. 2021. https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed December 15, 2021.
  48. Bogart M, Glassberg MB, Reinsch T, Stanford RH. Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting. Respir Med. 2018;145:138-144.
  49. Tkacz J, Evans K, Touchette D, et al. Prompt initiation of maintenance therapy in the United States (PRIMUS): an analysis of triple therapy following a disease exacerbation among patients with COPD. Chest. 2021;160(4 suppl):1809A-1810A.
  50. Quint JK, O’Leary C, Venerus A, et al. Prescribing pathways to triple therapy: a multi-country, retrospective observational study of adult patients with chronic obstructive pulmonary disease. Pulm Ther. 2020;6:333-350.
  51. Lipson DA, Barnhart F, Brealey N, et al; for the IMPACT investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671-1680.
  52. Rabe KF, Martinez FJ, Ferguson GT, et al; for the ETHOS investigators. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35-48.
  53. Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747-758. Errata in: Lancet Respir Med. 2018;6:e55; Lancet Respir Med. 2019;7:e9.
  54. Martinez FJ, Rabe KF, Ferguson GT, et al; for the ETHOS investigators. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease: a randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203:553-564.
  55. Lipson DA, Crim C, Criner GJ, et al; for the IMPACT investigators. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201:1508-1516.
  56. Bogart M, Stanford RH, Laliberté F, et al. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343-352.
  57. Ferguson GT, Brown N, Compton C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020;21:131.
  58. Lai CC, Chen CH, Lin CYH, et al. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2019;14:1539-1548. Erratum in: Int J Chron Obstruct Pulmon Dis. 2020;15:155-156.
  59. Bekkat-Berkani R, Wilkinson T, Buchy P, et al. Seasonal influenza vaccination in patients with COPD: a systematic literature review. BMC Pulm Med. 2017;17:79.
  60. Walters JAE, Tang JNQ, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017:CD001390.
  61. Tashkin DP. Smoking cessation in chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2015;36:491-507.
  62. Zhang A, Wang L, Long L, et al. Effectiveness and economic evaluation of hospital-outreach pulmonary rehabilitation for patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2020;15:1071-1083.
  63. Lindenauer PK, Stefan MS, Pekow PS, et al. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among Medicare beneficiaries. JAMA. 2020;323:1813-1823.
  64. Ridwan ES, Hadi H, Wu YL, Tsai PS. Effects of transitional care on hospital readmission and mortality rate in subjects with COPD: a systematic review and meta-analysis. Respir Care. 2019;64:1146-1156.
  65. Pérez Valdés CR, Lenoir A, Nicod L. COPD exacerbation and prevention. Cardiovasc Med. 2017;20:38-45.
  66. Pleasants RA, Riley IL, Mannino DM. Defining and targeting health disparities in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:2475-2496.
  67. Miller S. Screenings and early intervention can reduce medical costs. Society for Human Resource Management. April 19, 2012. www.shrm.org/resourcesandtools/hr-topics/benefits/pages/earlyintervention.aspx. Accessed May 8, 2020.
  68. Blanchette CM, Gross NJ, Altman P. Rising costs of COPD and the potential for maintenance therapy to slow the trend. Am Health Drug Benefits. 2014;7(2):98-106.
Related Items
Implementation Strategies of Biosimilars in Healthcare Systems: The Path Forward
Raymond K. Cross, MD, MS, Amy L. Stewart, MSN, RN, FNP-C, Colin C. Edgerton, MD, FACP, FACR, RhMSUS, Bhavesh Shah, RPh, BCOP, John A. Welz, MPH, Jonathan Kay, MD
June 2022 Vol 15, No 2 published on June 23, 2022 in Business, Review Article
Multiple Sclerosis: Systemic Challenges to Cost-Effective Care
David R. Weinstein, PhD, Gary M. Owens, MD, Ankit Gandhi, PharmD
March 2022 Vol 15, No 1 - Online Only published on March 23, 2022 in Business, Review Article
Migration of Hospital Total Hip and Knee Arthroplasty Procedures to an Ambulatory Surgery Center Setting and Postsurgical Opioid Use: A Private Practice Experience
James Van Horne, MD, Alaine Van Horne, BS, Nick Liao, MS, Victoria Romo-LeTourneau, PharmD
March 2022 Vol 15, No 1 - Online Only published on March 23, 2022 in Original Research, Clinical
Correlation Between Atherosclerotic Cardiovascular Disease Risk Factors and Statin Prescribing Patterns
Fahamina Ahmed, PharmD, Shelby Gross, PharmD, Samah Hammad, PharmD Candidate, Candice Wilson, MPH, Batool Zeini, PharmD, George Nawas, PharmD, BCPS
December 2021 Vol 14, No 4 published on December 29, 2021 in Clinical, Original Research
Mental Illness Disclosure in the Workplace: An Opportunity for Improvement
Gary Branning, MBA, Heidi C. Waters, PhD, Christy R. Houle, PhD, MPH, Stacey L. Worthy, Esq, Betsy Fink, MBA, PMP, Katie Hayes
December 2021 Vol 14, No 4 published on December 29, 2021 in Clinical, Review Article
Last modified: July 12, 2022
Copyright © Engage Healthcare Communications, LLC. All rights reserved.